Have Been Scheduled
BCR - Upcoming Dividend Payouts
Next Ex-Dividend Date
|Amount||Declare Date||Ex-Dividend Date ▲||Record Date||Pay Date||Payout Type|
|No Upcoming Dividend Dates|
BCR - Dividend Yield & Stock Price History
Current Dividend Yield
BCR - Dividend Payout History
Current Annual Payout
Dividend.com DARS Rating™ Breakdown for BCR
BCR - Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal Dividend Growth History for BCR.||5.4%||5.1%||42 years|
BCR - Historical Annual Dividend Data & Growth
Payouts Increasing For
|Payout Amount||Calendar Year||Annual Growth|
BCR - Historical Dividend Data
Payouts Increasing For
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
C.R. Bard, Inc. (BCR) - News
Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Wednesday's Analyst Moves: GNC Holdings Inc, Medtronic, Inc., Tyson Foods, Inc., More (GNC, MDT, TSN, More)Jun 18, 2014Before Wednesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
After a few weeks of setting record highs, the markets pulled back today, as the World Bank announced a reduction in its global growth forecast. In...
Today's After Hours Earnings: Amgen, Inc., C.R. Bard, Inc., Discover Financial Services, More (AMGN, BCR, DFS, More)Apr 22, 2014After the bell on Tuesday, a few big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings reports...
Citigroup Raises Price Target on C.R. Bard (BCR)Oct 14, 2013Citigroup announced on Monday that it has raised its price target on C.R. Bard, Inc. (BCR) from $123.00 to $124.00. The firm also reiterated its Neutral rating on the company. Commenting on the increased price target, Citigroup analyst Mathew J. Dodds noted "We are adjusting our BCR estimates to reflect the continued delay in the Gore court decision and the completion of the Medafor acquisition. We are now assuming a Gore royalty start in 1Q14 and expect the Medafor acquisition to be slightly EPS accretive in 2014. For 3Q13, we have raised our Soft Tissue Repair estimates due to the full US release of Phasix resorbable mesh." C.R. Bard shares traded 1.01% higher during Monday's session. Year-to-date, the stock is up 16.94%.
C.R. Bard to Acquire Rochester Medical for $262 Million (BCR, ROCM)Sep 4, 2013C.R. Bard, Inc. (BCR) announced on Wednesday that it will acquire urine drainage care product company, Rochester Medical Corporation (ROCM). BCR will purchase ROCM for about $262 million, or $20 per share. This acquisition will help BCR expand its urology homecare market. The deal is expected to close later this year. C.R. Bard shares were mostly flat during pre-market trading Wednesday. The stock is up 17% YTD. Rochester Medical shares were up $6.04, or 43.74%, during pre-market trading Wednesday. The stock is up 37% YTD. The Bottom Line Shares of C.R. Bard, Inc. (BCR) have a 0.73% yield, based on Tuesday's closing price of $114.66. C.R. Bard, Inc. (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Bank Of America Boosts Price Target on C.R. Bard, Inc. (BCR)Aug 29, 2013Bank of America announced on Thursday that it is maintaining its "Buy" rating on the New Jersey-based medical device manufacturer C.R. Bard, Inc. (BCR) , and also went onto raise its price target for the company. Bob Hopkins, an analyst with the bank, noted that they are raising their price target on C.R. Bard following a meeting with the company's CEO and CFO. Hopkins added that C.R. Bard's financial outlook is promising, noting, "BCR remains broadly out of favor, but we see a clear pathway to accelerating growth and upside to numbers and we view the risk reward on near term catalysts as very favorable. BCR trades at 11.8x our view of BCR's potential 2015 cash earnings power and the average medtech company trades at about 12.3x 2015 cash EPS. We argue BCR is an accelerating growth story with a better than average growth outlook, similar risk and near term catalysts." C.R. Bard shares rallied higher on Thursday, gaining 1.37% on the day. The stock is up 18% YTD. The Bottom Line Shares of C.R. Bard, Inc. (BCR) are yielding 0.73% based on Thursday's closing price of $115.71. C.R. Bard, Inc. (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
CL King Downgrades C.R. Bard, Inc. (BCR)Jun 26, 2013CL King announced today that it has downgraded healthcare supplier C.R. Bard, Inc (BCR) from "Buy" to "Neutral." The company, which manufactures a slew of surgical products, has recently come under fire after it was discovered that a plastic unfit for use in humans was used in one of C.R. Bard's surgical mesh devices. Prior to this, C.R. Bard had just recently resolved a $50 million lawsuit over alleged payments made to doctors to promote its devices. Despite these incidents, shares of C.R. Bard are up 6.80% year-to-date. During Wednesday's session, the stock was down 0.33% or 36 cents. The Bottom Line Shares of C.R. Bard, Inc (BCR) have a dividend yield of 0.77% based on Wednesday's closing price of $108.39 and its annual payout of 84 cents. C.R. Bard, Inc (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts C.R. Bard Inc.(BCR) has...
The following companies announced a change in their dividend payouts today. Companies Increasing Dividend Payouts C.R. Bard, Inc. (BCR) has...